A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

NCT07702890 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

188

Enrollment

INDUSTRY

Sponsor class

Conditions

Obesity
Type 2 Diabetes

Interventions

DRUG: GUB-UCN2
DRUG: Placebo

Sponsor

Gubra A/S